Mode
Text Size
Log in / Sign up

Meta-analysis links ceftriaxone to higher 30-day mortality in MSSA bloodstream infectionsCeftriaxone May Increase Death Risk In Bloodstream Infections

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider avoiding ceftriaxone as initial therapy for MSSA bloodstream infections due to increased 30-day mortality risk.

This systematic review and meta-analysis of observational studies evaluated the comparative effectiveness of ceftriaxone versus standard-of-care (antistaphylococcal penicillins or cefazolin) for patients with methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections, including 2568 patients. The primary outcome was 30-day and 90-day all-cause mortality; secondary outcomes included clinical success, microbiological clearance, and adverse event rates.

The meta-analysis found that ceftriaxone was associated with significantly higher 30-day all-cause mortality (OR 3.33; 95% CI 2.17-5.10), indicating potential harm. However, 90-day all-cause mortality was not significantly different between groups (OR 1.71; 95% CI 0.75-3.90). Secondary outcomes, including clinical success (OR 0.49; 95% CI 0.19-1.26) and microbiological clearance (OR 1.66; 95% CI 0.73-3.82), also showed no significant differences. Adverse event rates were similar between groups.

Important limitations include the observational nature of the included studies, meaning the association does not imply causation. No randomized trials were included, and the analysis did not adjust for potential confounders. The authors note that routine use of ceftriaxone for MSSA bloodstream infections, especially as initial therapy, is not supported by current evidence. Clinicians should interpret these findings cautiously, as 90-day mortality and secondary outcomes were not significantly different, and the evidence is based on observational data.

Ceftriaxone May Increase Death Risk In Bloodstream Infections

Imagine a patient fighting a serious infection in their blood. They are in the hospital and need strong medicine to survive. Doctors usually have a few trusted options to fight these germs. But sometimes, a drug that seemed safe might actually make things worse.

This new study looks at a common antibiotic called ceftriaxone. Many doctors use it because it is easy to give once a day. It also has a good safety record for many conditions. However, this review found a scary problem when treating specific bloodstream infections.

Blood infections caused by methicillin-susceptible Staphylococcus aureus are very dangerous. These germs are often called MSSA. They can spread quickly through the bloodstream and cause sepsis. Sepsis is a life-threatening reaction to infection that kills many people every year.

For decades, doctors have treated these infections with antistaphylococcal penicillins or cefazolin. These drugs are the standard of care. They work well to kill the bacteria and save lives. Ceftriaxone was chosen as an alternative because it is convenient. But the evidence for its use in this specific situation has always been mixed.

But here is the twist. This new analysis of eleven studies changed the picture. Researchers looked at data from over 2,500 patients. They compared ceftriaxone to the standard drugs used today. The results were not what anyone expected.

The study found that patients given ceftriaxone had a much higher risk of dying within 30 days. The odds of death were more than three times higher than with standard treatment. This difference was clear and consistent across many different hospitals and countries.

How does this happen. Think of the bacteria as a lock and the drug as a key. The standard drugs fit the lock perfectly and shut the door on the infection. Ceftriaxone might not fit the lock as well for this specific type of staph. It fails to stop the bacteria from growing effectively.

The bacteria can multiply while the drug is doing nothing. This allows the infection to spread and the patient to get sicker. The body cannot fight the infection alone when the medicine is not working. This leads to organ failure and death in the early stages of treatment.

The study included data from many different sources. They looked at death rates at 30 days and 90 days. They also checked for clinical success and clearing the bacteria from the blood. The 90-day death rate did not show a big difference. But the first month is critical for survival.

This does not mean ceftriaxone is useless for all infections.

The drug works well for many other conditions. It is great for pneumonia or urinary tract infections. The problem is specific to bloodstream infections caused by this type of staph. Doctors must know the difference between these uses.

Adverse events were similar between the groups. Patients did not get more side effects from ceftriaxone. The issue was not toxicity but a lack of effectiveness. The drug simply could not kill the bacteria fast enough to prevent death.

What does this mean for patients. If you have a bloodstream infection, your doctor will choose the best drug. They should avoid ceftriaxone as the first choice. Using the standard drugs gives you the best chance of survival.

This finding comes from a systematic review. This means researchers looked at all available studies on the topic. They did not just pick one study to support their point. The conclusion is based on a large pool of evidence. Only new randomized studies might change this advice in the future.

The road ahead involves more research. Scientists need to test new drugs that work better. They must also study why ceftriaxone fails in this specific case. Until then, the current standard of care remains the safest option.

Doctors will need to update their guidelines soon. They will likely stop recommending ceftriaxone for this condition. Patients should ask their doctors about the best treatment options. Knowing the risks helps everyone make informed decisions.

The takeaway is clear. Do not assume an old drug is always safe. Always check the latest evidence for serious infections. Your life depends on the right choice of medicine.

Study Details

Study typeMeta analysis
Sample sizen = 2,568
EvidenceLevel 1
PublishedDec 2026
View Original Abstract ↓
BACKGROUND: Bloodstream infections (BSIs) by methicillin-susceptible Staphylococcus aureus (MSSA) are a significant cause of morbidity and mortality, traditionally treated with antistaphylococcal penicillins (ASPs) or cefazolin. Ceftriaxone has emerged as an alternative due to its once-daily dosing regimen and favourable safety profile; however, its efficacy compared to the standard of care (SoC) remains controversial. This evidence synthesis aimed to assess the role of ceftriaxone in treating MSSA-BSIs. METHODS: A systematic literature search was conducted in PubMed, Embase, and Scopus up to December 31, 2025 (PROSPERO protocol CRD42024595748). Studies comparing ceftriaxone to ASPs or cefazolin for MSSA-BSIs were included. Primary outcomes were 30-day and 90-day all-cause mortality . Pooled effect sizes with their 95% confidence intervals (CIs), were calculated using random-effects models, odds ratios (ORs) and mean differences (MDs) according to the type of outcome. RESULTS: Eleven studies totalling 2,568 patients were included. Ceftriaxone was associated with significantly increased 30-day mortality (OR 3.33; 95% CI: 2.17-5.10), although differences at 90 days were not significant (OR 1.71; 95% CI: 0.75-3.90). No significant differences were noted for clinical success (OR 0.49; 95% CI: 0.19-1.26), microbiological clearance (OR 1.66; 95% CI: 0.73-3.82). Adverse event rates were similar between groups. CONCLUSION: Given the availability of various alternatives and the consistent short-term mortality signal observed, routine use of ceftriaxone for MSSA-BSIs, especially as initial therapy, is not supported by current evidence. Only novel findings from randomized studies may change the place in therapy of the drug in this context.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.